⌘K
Loading ticker…
Skye Bioscience, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Skye Bioscience, Inc. Common Stock (SKYE) has a 3-month relative strength percentile of 58 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 38. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 8.4%, relative volume 0.81×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
58 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
SKYE is in a stage 4 downtrend, week 4. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -15.3% / -45.5%.
No attention data for this ticker yet — it joins the daily scan once a baseline builds.
SKYE is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $345K notional.
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $345K |
| VXFVanguard Extended Market ETF | 0.00% | $114K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SKYE Jan avg: 24.07% median: 24.07% win: 100% σ: 15.06% n: 2 2024-04-12 → 2026-05-29 | SKYE Feb avg: -18.73% median: -18.73% win: 0% σ: 10.63% n: 2 2024-04-12 → 2026-05-29 | SKYE Mar avg: -30.85% median: -30.85% win: 0% σ: 18.89% n: 2 2024-04-12 → 2026-05-29 | SKYE Apr avg: 27.33% median: 37.11% win: 100% σ: 22.23% n: 3 2024-04-12 → 2026-05-29 | SKYE May avg: -10.38% median: -10.21% win: 0% σ: 1.31% n: 3 2024-04-12 → 2026-05-29 | SKYE Jun avg: 40.05% median: 40.05% win: 50% σ: 100.49% n: 2 2024-04-12 → 2026-05-29 (current) | SKYE Jul avg: -25.02% median: -25.02% win: 0% σ: 14.75% n: 2 2024-04-12 → 2026-05-29 | SKYE Aug avg: 8.88% median: 8.88% win: 50% σ: 15.34% n: 2 2024-04-12 → 2026-05-29 | SKYE Sep avg: -12.27% median: -12.27% win: 50% σ: 34.73% n: 2 2024-04-12 → 2026-05-29 | SKYE Oct avg: -13.27% median: -13.27% win: 50% σ: 66.88% n: 2 2024-04-12 → 2026-05-29 | SKYE Nov avg: -14.90% median: -14.90% win: 0% σ: 0.83% n: 2 2024-04-12 → 2026-05-29 | SKYE Dec avg: -39.87% median: -39.87% win: 0% σ: 4.10% n: 2 2024-04-12 → 2026-05-29 |